natgillin/translations-raw huggingface dataset:
The first study was conducted in 2000 with the veterinary medicinal product ‘Zanil Fluke Drench' at the single maximum recommended dose volume of 105 ml of product per animal and in accordance with the VICH Guideline 482. 
Prvo je ispitivanje provedeno 2000. godine uz veterinarsko-medicinski proizvod „Zanil Fluke Drench” u količini jedne maksimalne preporučene doze od 105 ml po životinji te u skladu s 48. smjernicom Međunarodne suradnja za harmonizaciju tehničkih zahtjeva za registraciju veterinarsko-medicinskih proizvoda (VICH)2.
The CVMP considered that the withdrawal periods for milk, meat and offal derived from treated cattle, sheep and goats should be amended as proposed to provide assurance for consumer safety. 
CVMP smatra da razdoblje karencije za mlijeko, meso i iznutrice liječenih goveda, ovaca i koza treba prilagoditi prema prijedlogu kako bi se osigurala sigurnost potrošača.
Based on this study, in which residues in all tissues were below the MRL at day 10, and on the data reported in the CVMP EPMAR for oxyclozanide (EMEA/MRL/889/03-FINAL), where total residues were below the MRLs in all tissues at the 14 day timepoint, a withdrawal period of 14 days is retained. 
Na temelju tog ispitivanja u kojem su rezidui u svim tkivima bili manji od najveće dopuštena količina rezidua 10. dana te podataka navedenih u EPMAR-u CVMP-a za oksiklozanid (EMEA/MRL/889/03-FINAL) o ukupnoj količini rezidua koja je bila manja od najveće dopuštene količine rezidua u svim tkivima 14. dan nakon primjene, zadržava se razdoblje karencije od 14 dana.
It was noted that a 14C-oxyclozanide radiolabelled study reported in paragraph 25 of the CVMP European Public MRL Assessment Report (EPMAR) for oxyclozanide (EMEA/MRL/889/03-FINAL)1 indicates that all total 14C-oxyclozanide residues were below the MRL at fourteen days and that they did not increase thereafter. 
Primijećeno je da se u 14radijski označenom ispitivanju C-oksiklozanida prijavljenom u odjeljku 25. Europskog javnog izvješća CVMP-a o procjeni najvećih dopuštenih količina rezidua (EPMAR) za oksiklozanid (EMEA/MRL/889/03-FINAL)1 navodi da je ukupna količina 14rezidua C-oksiklozanida bila manja od najveće dopuštene količine rezidua četrnaestog dana.
Two GLP-compliant residue depletion studies in cattle were submitted. 
Dostavljena su dva ispitivanja o izlučivanju rezidua u goveda u skladu s dobrom laboratorijskom praksom.
Overall summary of the scientific evaluation of Zanil and associated names, and generic products thereof (see Annex I) 
Cjelokupni sažetak znanstvene ocjene veterinarskomedicinskog proizvoda Zanil i pridruženih imena (vidi Prilog I.)
• the CVMP considered that the overall benefit-risk balance for the products under this procedure remains positive subject to amendments in the product information; the CVMP has recommended variations of the marketing authorisations for veterinary medicinal products Zanil and associated names, and generic products thereof remains positive (see Annex I) in order to amend the summaries of product characteristics, labelling and package leaflets in line with recommended changes in the product information as set out in Annex III. 
CVMP preporučuje da varijacije odobrenja za stavljanje u promet veterinarsko-medicinskog proizvoda Zanil i pridruženih imena te njegove generičke lijekove ostanu pozitivne (vidjeti Prilog I.) kako bi se izmijenili sažetci opisa svojstava VMP-a, označivanje i upute o VMP-u u skladu s preporučenim izmjenama u informacijama o VMP-u kako je utvrđeno u Prilogu III.
• a sheep and goat meat and offal withdrawal period of 14 days, 
• razdoblje karencije za meso i iznutrice ovce i koze iznosi 14 dana,
The product was administered to 22 cows at the single maximum recommended dose volume of 105 ml of product per animal and in accordance with the VICH Guideline 48. 
VMP je primijenjen na 22 krave u količini od jedne maksimalne preporučene doze od 105 ml VMP-a po životinji te u skladu s 48. smjernicom Međunarodne suradnja za harmonizaciju tehničkih zahtjeva za registraciju veterinarsko-medicinskih proizvoda (VICH).
Residue depletion data in sheep and goat milk 
Podatci o izlučivanju rezidua u mlijeku ovaca i koza
The highest residues levels (2 µg/kg i.e. 1/5 of the MRL) were observed in one cow at the second milking. 
1/5 najveće dopuštene količine rezidua) primijećena je kod jedne krave pri drugoj mužnji.
INN 
Down
Station Works Camlough Road Newry, Co. Down BT35 6JP 
Down BT35 6JP
France noted that for Zanil and associated names, and generic products thereof the Member States across the EU/EEA have established different withdrawal periods for milk, meat and offal derived from treated cattle and sheep. 
Francuska je napomenula da su države članice diljem EUa/EGP-a uspostavile različita razdoblja karencije za mlijeko, meso i iznutrice nastalo od liječenih goveda i ovaca za Zanil i pridružena imena te njihove generičke proizvode.
Evaluation and conclusions on the benefit-risk balance Having considered the grounds for referral and the available data, the CVMP concluded that the withdrawal periods for milk, meat and offal derived from treated cattle, sheep and goats should be amended as recommended to provide assurance for consumer safety. 
Uzimajući u obzir razloge za arbitražni postupak i dostupne podatke, CVMP smatra da razdoblje karencije za mlijeko, meso i iznutrice od liječenih goveda, ovaca i koza treba prilagoditi prema prijedlogu kako bi se osigurala sigurnost potrošača.
Whereas 
Co.
Based on this, considering that in the study with the combination product ‘Nilzan Drench Plus', residues were also measured in the untreated control, the results seen in the ‘Nilzan Drench Plus' study at day 21 were considered to be outliers and excluded from the analysis. 
Na temelju navedenog, uzimajući u obzir da su u ispitivanju nakon primjene kombiniranog VMP-a „Nilzan Drench Plus“ također izmjereni rezidui
In view of deficiencies noted in the ‘Nilzan Drench Plus' study, namely the fact that the product used was a combination product (oxyclozanide and levamisole) instead of the mono-product Zanil 
Uzimajući u obzir nedostatke primijećene u ispitivanju VMP-a „Nilzan Drench Plus”, odnosno to što je korišteni lijek bio kombinirani lijek (oksiklozanid i levamisol) umjesto monolijeka Zanil (oksiklozanid) i abnormalne rezultate koji su primijećeni 21. dana, smatra se da je potrebno uvesti sigurnosni faktor od barem 30 % pri utvrđivanju razdoblja karencije.
Belgium Merial SAS 29 avenue Tony Garnier 69007 Lyon 
Nizozemska Merial SAS 29 avenue Tony Garnier 69007 Lyon
No other residue depletion data in cattle milk were provided by the applicants/marketing authorisation holders. 
Podnositelji zahtjeva/nositelji odobrenja za stavljanje u promet nisu dostavili druge podatke o izlučivanju rezidua u mlijeko goveda.
No other residue depletion data in sheep meat and offal were provided by the applicants/marketing authorisation holders. 
Podnositelj zahtjeva/nositelj odobrenja za stavljanje u promet nije dostavio druge podatke o izlučivanju rezidua u meso i iznutrice ovaca.
No other residue depletion data in cattle meat and offal were provided by the applicants/marketing authorisation holders. 
Podnositelj zahtjeva/nositelj odobrenja za stavljanje u promet nije dostavio druge podatke o izlučivanju rezidua u meso i iznutrice goveda.
1 CVMP European Public MRL Assessment Report for oxyclozanide (EMEA/MRL/889/03-FINAL) - link 
1 CVMP European Public MRL Assessment Report for oxyclozanide (EMEA/MRL/889/03-FINAL) - link u životinja iz kontrolne skupine koje nisu liječene, rezultati primijećeni u ispitivanju VMP-a „Nilzan Drench Plus“ 21. dana smatraju se izuzetnima te su isključeni iz analize.
Some cases may require longer treatment. 
Neki slučajevi mogu zahtijevati dulje liječenje.
Additional polar metabolites also exist. 
Također postoje i dodatni polarni metaboliti.
Do not use in male breeding dogs. 
Ne primjenjivati u muških rasplodnih pasa.
Date of last renewal: 10 April 2008 
Datum posljednjeg produljenja odobrenja: 10. travnja 2008.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 30 tablets 
SADRŽAJ PO TEŽINI, VOLUMENU ILI BROJU DOZA 30 tableta
Clomicalm should be used under veterinary supervision. 
Clomicalm treba koristiti pod nadzorom veterinara.
In dogs, the volume of distribution (VDss) is 3.8 l/kg. 
Kod pasa volumen distribucije (VDss) je 3,8 l/kg.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/ . 
Detaljne informacije o ovom veterinarsko-medicinskom proizvodu dostupne su na web stranici Europske agencije za lijekove http://www.ema.europa.eu/.
Shelf-life of the veterinary medicinal product as packaged for sale: 4 years 
Rok valjanosti veterinarsko-medicinskog proizvoda kad je zapakiran za prodaju: 4 godine.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet of Clomicalm contains: 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna tableta Clomicalma sadrži:
The efficacy and safety of Clomicalm has not been established in dogs weighing less than 1.25 kg or under six months of age. 
Neškodljivost i djelotvornost Clomicalma nije utvrđena u pasa koji teže manje od 1,25 kg ili u onih mlađih od šest mjeseci.
In cases showing no improvement after 2 months, treatment with Clomicalm should be ceased. 
U slučaju da nema poboljšanja nakon dva mjeseca, liječenje Clomicalmom treba prekinuti.
MARKETING AUTHORISATION NUMBERS EU/2/98/007/001-003 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/98/007/001-003
Do not use after the expiry date which is stated on the label after EXP. 
Ne koristite veterinarsko-medicinski proizvod poslije isteka roka valjanosti naznačenog na etiketi poslije „EXP“.
Clomipramine and its metabolites are rapidly distributed in the body in mice, rabbits, and rats with high concentrations being achieved in organs and tissues (including the lungs, heart and brain) and low concentrations remaining in the blood. 
Klomipramin i njegovi metaboliti brzo se distribuiraju u tijelu miševa, kunića i štakora, s visokim koncentracijama u organima i tkivima (uključujući pluća, srce i mozak) i niskim koncentracijama koje zaostaju u krvi.
EXPIRY DATE EXP {month/year} 
ROK VALJANOSTI EXP: {mjesec/godina}
The safety of the veterinary medicinal product has not been established in female dogs during pregnancy and lactation. 
Neškodljivost veterinarsko-medicinskog proizvoda nije utvrđena u ženki pasa tijekom graviditeta i laktacije.
One HDPE bottle with child resistant closure and sealing disk, containing 30 tablets and one silica gel desiccant sachet, packed within a cardboard box. 
Jedna HDPE boca sa sigurnosnim zatvaračem za djecu i zapornim diskom koja sadrži 30 tableta i jednu vrećicu silikagela kao sredstvo za sušenje zapakiranu unutar kartonske kutije.
Laboratory animal studies in mice and rats have shown evidence of embryotoxic effects. 
Laboratorijska ispitivanja na miševima i štakorima dokazala su embriotoksične učinke.
Pharmacotherapeutic group: Non-selective monoamine re-uptake inhibitors, ATCvet code: QN06AA04. 
Farmakoterapijska grupa: Neselektivni inhibitori ponovne pohrane monoamina ATCvet kod: QN06AA04
Still higher doses (725 mg/kg) produced, in addition, convulsions and death. 
Još više doze (725 mg/kg) uz to su uzrokovale konvulzije i smrt.
Simultaneous administration with cimetidine may lead to increased plasma levels of clomipramine. 
Istodobna primjena s cimetidinom može uzrokovati povišene plazmatske razine klomipramina.
The active components in vivo are clomipramine and its major metabolite, desmethylclomipramine. 
Djelatne komponente in vivo su klomipramin i njegov glavni metabolit, desmetilklomipramin.
It therefore possesses the properties of a serotonin re-uptake inhibitor and a tricyclic antidepressant. 
Stoga posjeduje svojstva inhibitora ponovne pohrane serotonina i tricikličkog antidepresiva.
Clomicalm may be given with or without food. 
Clomicalm se može dati s hranom ili bez nje.
Colloidal anhydrous silica Magnesium stearate 
Koloidni bezvodni silikagel Magnezijev stearat
The major route of biotransformation of clomipramine is demethylation to desmethylclomipramine. 
Glavni put biotransformacije klomipramina je demetilacija u desmetilklomipramin.
Clomipramine is extensively bound to plasma proteins (>97 %) in dogs. 
Klomipramin se ekstenzivno veže za proteine plazme u pasa (> 97 %).
Clomicalm may very rarely cause vomiting, changes in appetite, lethargy or an elevation in liver enzymes, which is reversible when the product is discontinued. 
Clomicalm može vrlo rijetko uzrokovati povraćanje, promjene apetita, letargiju ili povišenje jetrenih enzima, što je reverzibilno nakon prekida primjene proizvoda.
As an aid in the treatment of separation-related disorders in dogs manifested by destruction and inappropriate elimination (defaecation and urination) and only in combination with behavioural modification techniques. 
Kao pomoć u liječenju poremećaja povezanih s razdvajanjem u pasa koji se očituju destrukcijom i neodgovarajućom eliminacijom (defekacijom i mokrenjem) i samo u kombinacijama s tehnikama bihevioralne modifikacije.
Any unused veterinary medicinal product or waste materials derived form such veterinary medicinal products should be disposed of in accordance with local requirements. 
Bilo koji neupotrebljeni veterinarsko-medicinski proizvod ili otpadni materijali dobiveni primjenom tih veterinarsko-medicinskih proizvoda trebaju se odlagati u skladu s lokalnim propisima.
Both clomipramine and desmethylclomipramine contribute to the effects of Clomicalm: clomipramine is a potent and selective 5-HT reuptake inhibitor while desmethylclomipramine is a potent and selective noradrenaline reuptake inhibitor. 
klomipramin i desmetilklomipramin pridonose učincima Clomicalma: klomipramin je potentni i selektivni inhibitor ponovne pohrane 5-HT, dok je desmetilklomipramin potentni i selektivni inhibitor ponovne pohrane noradrenalina.
Clomipramine is well absorbed (>80%) from the gastrointestinal tract in dogs when administered orally but the systemic bioavailability for clomipramine and desmethylclomipramine is 22-26% due to extensive first pass metabolism by the liver. 
Klomipramin se dobro apsorbira (> 80 %) iz probavnog sustava pasa kad se primjenjuje peroralno, ali je sistemska bioraspoloživost za klomipramin i desmetilklomipramin 22 - 26 % zbog ekstenzivnog metabolizma prvog prolaska kroz jetru.
The elimination t1/2 after intravenous administration of clomipramine hydrochloride in dogs was 6.4 hours for clomipramine and 3.6 hours for desmethylclomipramine. 
Poluvrijeme eliminacije t1/2 nakon intravenske primjene klomipraminklorida u pasa iznosilo je 6,4 sati za klomipramin i 3,6 sati za desmetilklomipramin.
Do not use in case of known hypersensitivity to clomipramine and related tricyclic antidepressants. 
Ne primjenjivati u slučaju poznate preosjetljivosti na klomipramin i srodne tricikličke antidepresive.
In clinical trials, a treatment time of 2-3 months with Clomicalm in combination with behavioural modification techniques was sufficient to control the symptoms of separation-related disorders. 
U kliničkim ispitivanjima vrijeme liječenja Clomicalmom u trajanju od dva do tri mjeseca u kombinaciji s tehnikama bihevioralne modifikacije bilo je dostatno za kontrolu simptoma poremećaja povezanih s razdvajanjem.
People with known hypersensitivity to clomipramine should administer the product with caution. 
Osobe s utvrđenom preosjetljivošću na klomipramin proizvod trebaju primjenjivati s oprezom.
Manufacturer for batch release: Elanco France S.A.S. 
Proizvođač odgovoran za puštanje serije u promet: Elanco France S.A.S.
Vomiting may be reduced by co-administration with a small quantity of food. 
Povraćanje se može reducirati primjenom s malom količinom hrane.
One side bears the imprint ‘CG', the other ‘D/V' and a score. 
S jedne je strane otisak ‘CG', a s druge otisak ‘D/V' i prorez.
Overdose in human beings causes anticholinergic effects although central nervous and cardiovascular systems may also be affected. 
Predoziranja u ljudi uzrokuje antikolinergičke učinke, iako i središnji živčani sustav i kardiovaskularni sustav također mogu biti zahvaćeni.
Clomicalm may be given orally with or without food. 
Clomicalm se može dati peroralno s hranom ili bez nje.
Clomipramine has a broad-spectrum of action in blocking the neuronal reuptake of both serotonin (5HT) and noradrenaline. 
Klomipramin ima široki spektar djelovanja u blokadi ponovne pohrane serotonina (5-HT) i noradrenalina u neurone.
Because of its potential anticholinergic properties, Clomicalm should also be used with care in dogs with narrow angle glaucoma, reduced gastrointestinal motility or urinary retention. 
Zbog njegovih potencijalnih antikolinergičnih svojstava, Clomicalm treba uvijek koristiti oprezno u pasa s glaukomom uskog kuta, smanjenom pokretljivošću crijeva ili urinarnom retencijom.
Vomiting may be reduced by co-administration of Clomicalm with a small quantity of food. 
Povraćanje se može reducirati primjenom Clomicalma s malom količinom hrane.
MARKETING AUTHORISATION NUMBER EU/2/98/007/001 (5 mg, 30 tablets) EU/2/98/007/002 (20 mg, 30 tablets) EU/2/98/007/003 (80 mg, 30 tablets) 
EU/2/98/007/002 (20 mg, 30 tableta) EU/2/98/007/003 (80 mg, 30 tableta)
Keep out of sight and reach of children as accidental ingestion should be regarded as serious. 
Čuvati izvan pogleda i dosega djece jer se slučajno gutanje treba smatrati ozbiljnim.
One side bears the imprint ‘I/I', the other no imprint and scored on both sides. 
S jedne je strane otisak ‘I/I', s druge nema otiska, a prorez se nalazi s obje strane.
In case of accidental ingestion, seek medical advice immediately and show the product label to the physician. 
U slučaju da se nehotice proguta, odmah potražite pomoć liječnika i pokažite mu uputu ili etiketu.
SPECIAL STORAGE CONDITIONS Store in the original container. 
POSEBNI UVJETI ČUVANJA Čuvati u originalnom spremniku.
One side bears the imprint ‘C/G', the other ‘G/N' and scored on both sides. 
S jedne je strane otisak ‘C/G', a s druge otisak ‘G/N' i prorez s obje strane.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE 
OSNOVNI PODACI KOJI SE MORAJU NALAZITI NA MALIM UNUTARNJIM PAKOVANJIMA
Accidental ingestion should be regarded as serious. 
Slučajno gutanje treba smatrati ozbiljnim.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports) 
Učestalost nuspojava određena je sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavu(e)) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja)
Excipients: For the full list of excipients, see section 6.1. 
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu 
Detaljne informacije o ovom veterinarsko-medicinskom proizvodu su dostupne na web stranici Europske agencije za lijekove (EMA) http://www.ema.europa.eu/.
In addition, clomipramine has anticholinergic effects by antagonism of cholinergic muscarinic receptors. 
Osim toga, djeluje antikolinergički antagonističkim djelovanjem na kolinergične muskarinske receptore.
Recommendations on the interaction between Clomicalm and other medicaments are derived from studies in species other than dogs. 
Preporuke o interakcijama između Clomicalma i drugih lijekova dobivene su iz ispitivanja na vrstama različitim od psa.
Administration of Clomicalm with food causes moderately higher plasma AUC values for clomipramine (25%) and desmethylclomipramine (8%) as compared with administration to fasted dogs. 
Primjena Clomicalma s hranom uzrokuje umjereno visoke vrijednosti AUC u plazmi za klomipramin (25 %) i desmetilklomipramin (8 %) u usporedbi s primjenom u pasa natašte.
At steady state, the ratio of plasma clomipramine to desmethylclomipramine concentrations is approximately 3:1. 
U ravnotežnom stanju, omjer plazmatskih koncentracija klomipramina i desmetilklomipramina iznosio je približno 3:1.
Plasma levels of certain anti-epileptic drugs, such as phenytoin and carbamazepine, may be increased by coadministration with Clomicalm. 
Plazmatske razine određenih antiepileptika, poput fenitoina i karbamazepina, mogu se povisiti uz istodobnu primjenu Clomicalma.
Higher doses (500 mg/kg i.e. 250 times the recommended dose) produced emesis, defecation, drooped eyes, trembling and quietness. 
Više doze (primjerice 500 mg/kg, tj. 250 puta veća doza od preporučene) uzrokovale su emezu, defekaciju, ptozu očnih kapaka, drhtanje i povučenost.
Repeated administration of Clomicalm causes moderate increases in plasma concentrations, accumulation ratios after oral administration twice daily were 1.2 for clomipramine and 1.6 for desmethylclomipramine, with steady state being reached within 3 days. 
Opetovana primjena Clomicalma uzrokuje umjerene poraste koncentracije lijeka u plazmi, a omjeri akumulacije nakon peroralne primjene dva put dnevno iznosili su 1,2 za klomipramin i 1,6 za desmetilklomipramin, s uravnoteženjem koncentracije unutar tri dana.
At overdose with 20 mg/kg Clomicalm (5 times the maximum therapeutic dose), bradycardia and arrhythmias (atrioventricular node block and ventricular escape beats) were observed approximately 12 hours after dosing. 
Prilikom predoziranja s 20 mg/kg Clomicalma (5 puta većom dozom od maksimalne terapijske doze), uočene su bradikardija i aritmija (blok atrioventrikularnog čvora i pomak otkucaja klijetke - bijeg ventrikula) približno 12 sati nakon doziranja.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation 1 April 1998 
Datum prvog odobrenja: 1. travnja 1998.
The administration of Clomicalm is not recommended in combination with, or within 2 weeks of therapy with, monoamine oxidase inhibitors. 
Primjena Clomicalma ne preporučuje se u kombinaciji s inhibitorima monoamin oksidaza ili unutar dva tjedna od terapije inhibitorima monoamin oksidazama.
The maximal plasma concentrations (Cmax) after oral administration of single doses of 2 mg/kg clomipramine hydrochloride were: 240 nmol/l for clomipramine and 48 nmol/l for desmethylclomipramine. 
nakon peroralne primjene pojedinačnih doza od 2 mg/kg klomipraminklorida bile su: 240 nmol/l za klomipramin i 48 nmol/l za desmetilklomipramin.
Pack size: 30 tablets 
Veličina pakovanja: 30 tableta.
THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN” 
RIJEČI “ČUVATI IZVAN POGLEDA
Special precautions for use in animals It is recommended that Clomicalm be administered to dogs with cardiovascular dysfunction or epilepsy with caution and only after an assessment of the benefit risk ratio. 
Preporučuje se Clomicalm primijeniti na psima s kardiovaskularnom disfunkcijom ili epilepsijom s oprezom i samo nakon procjene omjera koristi i rizika.
The principle route of excretion in dogs is via the bile (>80%) with the remainder via the urine. 
Glavni put izlučivanja u pasa je putem žuči (> 80
Clomicalm may potentiate the effects of the anti-arrhythmic drug quinidine, anticholinergic agents (e.g. atropine), other CNS active drugs (e.g. barbiturates, benzodiazepines, general anaesthetics, neuroleptics), sympathomimetics (e.g. adrenaline) and coumarin derivatives. 
Clomicalm može potencirati učinke antiaritmičkog lijeka kinidina, antikolinergičnih lijekova (primjerice atropina), drugih lijekova koji djeluju na SŽS (primjerice barbiturata, benzodiazepina, općih anestetika, neuroleptika), simpatomimetika (primjerice adrenalina) i derivata kumarina.
Overdose with 40 mg/kg (20 times the recommended dose) of Clomicalm produced hunched posture, tremors, flushed abdomen and decreased activity in dogs. 
Predoziranje s 40 mg/kg (20 puta većom dozom od preporučene) Clomicalma uzrokovalo je pogrbljen položaj, drhtavice, naduti trbuh i smanjenu aktivnost pasa.